These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
117 related articles for article (PubMed ID: 18030130)
1. Periocular cutaneous toxicity and cicatricial ectropion: a potential class effect of antineoplastic agents that inhibit EGFR signaling. Frankfort BJ; Garibaldi DC Ophthalmic Plast Reconstr Surg; 2007; 23(6):496-7. PubMed ID: 18030130 [No Abstract] [Full Text] [Related]
2. Cicatricial ectropion associated with treatment of metastatic colorectal cancer with cetuximab. Garibaldi DC; Adler RA Ophthalmic Plast Reconstr Surg; 2007; 23(1):62-3. PubMed ID: 17237696 [TBL] [Abstract][Full Text] [Related]
3. Newly recognized ocular side effects of erlotinib. Methvin AB; Gausas RE Ophthalmic Plast Reconstr Surg; 2007; 23(1):63-5. PubMed ID: 17237697 [TBL] [Abstract][Full Text] [Related]
4. Ocular adverse events of systemic inhibitors of the epidermal growth factor receptor: report of 5 cases. Saint-Jean A; Sainz de la Maza M; Morral M; Torras J; Quintana R; Molina JJ; Molina-Prat N Ophthalmology; 2012 Sep; 119(9):1798-802. PubMed ID: 22584020 [TBL] [Abstract][Full Text] [Related]
8. Severe acneiform skin reaction during therapy with erlotinib (Tarceva), an epidermal growth factor receptor (EGFR) inhibitor. Eames T; Landthaler M; Karrer S Eur J Dermatol; 2007; 17(6):552-3. PubMed ID: 17951151 [No Abstract] [Full Text] [Related]
9. Clinical impact of switching to a second EGFR-TKI after a severe AE related to a first EGFR-TKI in EGFR-mutated NSCLC. Takeda M; Okamoto I; Tsurutani J; Oiso N; Kawada A; Nakagawa K Jpn J Clin Oncol; 2012 Jun; 42(6):528-33. PubMed ID: 22457323 [TBL] [Abstract][Full Text] [Related]
10. Temporal dependence of the effect of radiation on erlotinib-induced skin rash. Lacouture ME; Hwang C; Marymont MH; Patel J J Clin Oncol; 2007 May; 25(15):2140; author reply 2141. PubMed ID: 17513824 [No Abstract] [Full Text] [Related]
11. Class act: safety comparison of approved tyrosine kinase inhibitors for non-small-cell lung carcinoma. Burotto M; Ali SA; O'Sullivan Coyne G Expert Opin Drug Saf; 2015 Jan; 14(1):97-110. PubMed ID: 25345687 [TBL] [Abstract][Full Text] [Related]
12. Ten lessons from EGFR. Nakanishi Y Respir Investig; 2014 May; 52(3):151-2. PubMed ID: 24853013 [No Abstract] [Full Text] [Related]